Patents Assigned to Institute Curie
-
Publication number: 20240269282Abstract: The invention relates to methods and pharmaceutical compositions for the treatment and diagnosis of cancer. The invention also relates to methods and pharmaceutical compositions for the treatment of inflammatory diseases and autoimmune diseases. The inventors investigate the role and specific contribution of extracellular vesicles (EVs) in cancer environment. The inventors demonstrate that CSF1-associated EVs induce macrophage signature associated with T cell infiltration and extended patient survival. The inventors demonstrate that via specific extracellular vesicles, these tumors promote pro-inflammatory macrophages correlated with better clinical outcome and a better prognosis in TNBC patients. In the present invention, the inventors provide in vitro evidences towards a direct role of CSF1-associated EVs as tools, alone or with other immuno-therapies, to promote anti-tumor immune responses.Type: ApplicationFiled: May 10, 2022Publication date: August 15, 2024Applicants: Institut Curie, INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: Clotilde Thery, Mercedes Tkach
-
METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS
Publication number: 20240247318Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.Type: ApplicationFiled: February 14, 2024Publication date: July 25, 2024Applicants: Institute Curie, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Marc-Henri Stern, Elodie Manie, Tatiana Popova -
Publication number: 20240229122Abstract: The present disclosure relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising a step of subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers suitable for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence.Type: ApplicationFiled: February 6, 2024Publication date: July 11, 2024Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Universite de Versailles Saint-Quentin-en-YvelinesInventors: Charlotte Proudhon, Amélie Kasperek, Amanda Bortolini Silveira, François-Clément Bidard, Marc-Henri Stern
-
Publication number: 20240201192Abstract: The invention relates to tumor-associated FOLR2+ macrophages and gene signature thereof as a biomarker of favorable outcome and anti-tumor immunity useful for the prognosis and monitoring of cancer patients. The invention relates also to FOLR2+ macrophages as a therapeutic target for enhancing T cell immunity in the prevention and treatment of cancer and infectious diseases.Type: ApplicationFiled: April 12, 2022Publication date: June 20, 2024Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Universite Paris Cite, Centre National de la Recherche ScientifiqueInventors: Rodrigo Nalio Ramos, Pierre Guermonprez, Eliane Piaggio, Julie Helft
-
Publication number: 20240002776Abstract: The present invention relates to a device (2) for providing a liquid medium with a controlled flow rate and with a controlled concentration of a dissolved gas, the device (2) comprising: —a liquid reservoir (4) provided with: —at least one gas inlet (7); —at least one gas outlet (8); and—at least one liquid outlet (9); —an admission line (5) configured to provide a gaseous medium into the liquid reservoir (4), the admission line (5) being connected to the at least one gas inlet (7) and comprising at least one control valve (12); and an emission line (6) configured to withdraw the gaseous medium from the liquid reservoir (4), the emission line (6) being connected to the at least one gas outlet (8) and comprising at least one control valve (15). The present invention further relates to an assembly comprising said device, and to a method for providing a liquid medium with a controlled flow rate and with a controlled concentration in a dissolved gas.Type: ApplicationFiled: September 30, 2021Publication date: January 4, 2024Applicants: Sorbonne Universite, Centre National De La Recherche Scientifique, Institut Curie, FluigentInventors: William Cesar, Charlotte Bouquerel, Marine Verhulsel, Jean-Louis Viovy, Stéphanie Descroix
-
Publication number: 20230303974Abstract: The present invention relates to an engineered immune cell defective for SOCS1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of SOCS1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: July 30, 2021Publication date: September 28, 2023Applicants: Institut Curie, Institut National de la Santé et de la Recherche MédicaleInventors: Laurie Menger, Silvia Menegatti, Sebastian Amigorena
-
Publication number: 20230302050Abstract: The present application relates to fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof. The present invention further relates to functionalized drug nanocarriers, nucleic acids, vectors, host cells, immune cells comprising said sdAbs, and compositions comprising thereof, as well as their use for therapy.Type: ApplicationFiled: May 20, 2021Publication date: September 28, 2023Applicants: Institut Curie, Centre National de la Recherche Scientifique, The University of Zurich, Honing BiosciencesInventors: Sandrine Moutel, Franck Perez, Michele Bernasconi, Nagjie Laila Alijaj, Zélia Gouveia
-
Publication number: 20230293478Abstract: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Acute Myeloid Leukemia (AML).Type: ApplicationFiled: May 12, 2021Publication date: September 21, 2023Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, Peter MacCallum Cancer InstituteInventors: Raphaël RODRIGUEZ, Mark DAWSON, Sylvain GARCIAZ, Tatiana CANEQUE COBO
-
Publication number: 20230212243Abstract: The present application relates to a tumor specific neoantigenic peptide, wherein said peptide is encoded by a part of an ORF sequence from a transcript associated with a SF3B1 or a SF3B1-like mutation, comprises at least 8 amino acids and binds at least one MHC molecule with an affinity of less than 500 nM; and is not expressed in normal healthy cells. The present application further relates to vaccine or immunogenic composition, antibodies, T cell receptors, polynucleotides, vectors and immune cells derived thereof as well as their use in therapy of cancer.Type: ApplicationFiled: May 12, 2021Publication date: July 6, 2023Applicants: Institut Curie, Institut National de la Santé et de la Recherche MédicaleInventors: Olivier Lantz, Marc-Henri Stern, Jérémy Bigot, Alexandre Houy, Ana Ines Lalanne
-
Publication number: 20230183675Abstract: The present invention relates to the identification of a fully humanized single domain antibody scaffold as well as its use in generating synthetic single domain antibodies. The invention further relates to antigen-binding proteins comprising said single domain antibody scaffold and their use in therapy.Type: ApplicationFiled: May 20, 2021Publication date: June 15, 2023Applicants: Institut Curie, Centre National de la Recherche ScientifiqueInventors: Franck Perez, Sandrine Moutel
-
Publication number: 20230117652Abstract: The invention relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; and a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence. The invention also encompasses methods for the diagnosis and prognosis of cancer and a method for determining the efficacy of a cancer treatment.Type: ApplicationFiled: September 21, 2022Publication date: April 20, 2023Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Universite de Versailles Saint-Quentin-en-YvelinesInventors: Charlotte Proudhon, Amélie Kasperek, Amanda Bortolini Silveira, François-Clément Bidard, Marc-Henri Stern
-
Publication number: 20230107291Abstract: The invention relates to a method of identification of functional disease-specific, in particular tumor-specific, regulatory T cells and markers thereof. The invention also relates to the derived functional tumor-specific regulatory T cells, markers and engineered regulatory T cells and to their use for the diagnosis, prognosis, monitoring and treatment of cancer.Type: ApplicationFiled: February 22, 2021Publication date: April 6, 2023Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale, Institut Mutualiste MontsourisInventors: Eliane Piaggio, Wilfrid Richer, Christine Sedlik, Jimena Tosello, Joshua Waterfall, Elisa Bonnin
-
Publication number: 20220401539Abstract: The present disclosure relates to a tumor specific neoantigenic peptide, wherein said peptide (i) is encoded by a part of an (ORF) sequence from an unannotated transcript which transcription is positively regulated by an aberrant fusion protein, and (ii) is expressed at a higher level or frequency in a sample from said tumor compared to normal tissue sample. The present disclosure also relates to vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.Type: ApplicationFiled: October 22, 2020Publication date: December 22, 2022Applicants: Institut Curie, Institut National de la Santé et de la Recherche MédicaleInventors: Olivier Delattre, Olivier Saulnier, Joshua Waterfall, Céline Collin, Julien Vibert, Maud Gautier
-
Patent number: 11439724Abstract: The invention relates to a device for adsorbing odours comprising an absorbent layer and an adsorbent layer, said adsorbent layer being provided with a material permeable to volatile organic compounds (VOCs) and an adsorbent particulate filler comprising at least one spice. Such a device is particularly useful for adsorbing and masking body odours.Type: GrantFiled: June 23, 2020Date of Patent: September 13, 2022Assignees: Institute Curie, Ecole Superieure De Physique Et De Chimie Industrielle (ESPCI), Ecole Nationale Superieure De Chimie De Paris (ENSCP), Centre National De La Recherche Scientifique, Cemag CareInventors: Aurélie Thuleau, Isabelle Fromantin, Vincent Semetey, José Dugay, Jean-François Le Meur
-
Publication number: 20220193198Abstract: The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.Type: ApplicationFiled: March 27, 2020Publication date: June 23, 2022Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Eliane PIAGGIO, Sebastian AMIGORENA, Pamela CAUDANA, Felix REY, Gleyder ROMAN-SOSA, Pablo GUARDADO-CALVO
-
Patent number: 11236300Abstract: The present invention relates to a microfluidic device to manipulate, select, treat, or cultivate living bodies, comprising a first chamber, a second chamber and a network of guiding tracks, wherein: said network of guiding tracks comprises at least one first guiding track connecting the first chamber and the second chamber and at least one second guiding track connecting said at least one first guiding track with at least two interconnections; and said at least one second guiding track comprises a curved part; said curved part exhibiting a concavity facing the second chamber or the part of the network connected to the second chamber.Type: GrantFiled: October 21, 2016Date of Patent: February 1, 2022Assignees: Centre National de la Recherche Scientifique (CNRS), Institut Curie, Université de ParisInventors: Catherine Villard, Jean-Louis Viovy, Renaud Renault, Jean-Baptiste Durand, Jean-Michel Peyrin, Ivan Ferrante
-
Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
Patent number: 11149316Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.Type: GrantFiled: December 5, 2014Date of Patent: October 19, 2021Assignees: Institut Curie, INSERM (Institut National de la Sante et de la Recherche MedicaleInventors: Elodie Manie, Marc-Henri Stern, Tatiana Popova -
Publication number: 20210246518Abstract: The present invention relates to a method for detecting the interaction in a cell between a RNA and a protein, wherein the cell expresses: —the RNA fused to a hairpin, called hairpin-tagged RNA, —the protein fused to a tag, called tagged-protein, —a reporter protein fused to a protein which binds to said hairpin, wherein said reporter protein is a luminescent reporter protein, said method comprises the lysis of the cell and the detection of the complex tagged protein/hairpin-tagged RNA/hairpin binding protein—reporter protein.Type: ApplicationFiled: September 9, 2019Publication date: August 12, 2021Applicants: Centre National de la Recherche Scientifique, Institut Naitonal de la Sante et de la Recherche Medicale, Institut CurieInventor: Alena Shkumatava
-
Patent number: 11077121Abstract: The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.Type: GrantFiled: March 30, 2016Date of Patent: August 3, 2021Assignees: Institute For Cancer Research, Institut Curie, Institut de Genetique et de Biologie Moleculaire et CellulaireInventors: Alfonso Bellacosa, Rossella Tricarico, Tim Yen, Vikram Bhattacharjee, Pietro Mancuso, Lionel Larue, Irwin Davidson
-
Publication number: 20210161887Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.Type: ApplicationFiled: April 3, 2019Publication date: June 3, 2021Applicants: Universite de Bretagne Occidentale, Centre Hospitalier Regional Universitaire de Brest, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Institut Curie, Université de Paris, Univ Paris XIII Paris-Nord Villetaneuse, Universite Paris-SaclayInventors: Marc Blondel, Alicia Quillevere, Cécile Voisset, Maria José Lista, Robin Fahraeus, Chrysoula Daskalogianni, Rodrigo Prado-Martins, Marie-Paule Teulade-Fichou, Anton Granzhan, Claire Beauvineau, Oksana Reznichenko